Novartis Adds New Therapies As Shares Trade Below Analyst Value Targets
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Novartis Rhapsido® receives European Commission approval
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
Novartis Expands Cancer Drug Portfolio with $3 Billion Acquisition
In a strategic move to bolster its cancer medication offerings, Novartis has entered into a definitive agreement…
Novartis to buy experimental breast cancer drug in up to $3 billion deal
FRANKFURT, March 20 (Reuters) – Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate…
25 Year Anniversary of Innovation in Treating CML
Twenty-Five Years of Community: How Living With CML Has Changed—and Brought Patients Together Discussion notes from the Second…
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe…